BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24143252)

  • 21. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?
    Mahnert B; Tauber S; Kriegmair M; Nagel D; Holdenrieder S; Hofmann K; Reiter W; Schmeller N; Stieber P
    Clin Chem Lab Med; 2003 Jan; 41(1):104-10. PubMed ID: 12636058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of patients with microscopic hematuria who are at greater risk for the presence of bladder tumors using a dedicated questionnaire and point of care urine test--a study by the members of Association of Urooncology, Turkey.
    Turkeri L; Mangir N; Gunlusoy B; Yildirim A; Baltaci S; Kaplan M; Bozlu M; Mungan A
    Asian Pac J Cancer Prev; 2014; 15(15):6283-6. PubMed ID: 25124612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Role of immunocytology in the evaluation of patients with painless gross hematuria].
    Schmitz-Dräger BJ; Tirsar LA; Schmitz-Dräger C; Dörsam J; Ebert T; Bismarck E
    Urologe A; 2010 Jun; 49(6):741-6. PubMed ID: 20373094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.
    Parekattil SJ; Fisher HA; Kogan BA
    J Urol; 2003 Mar; 169(3):917-20. PubMed ID: 12576812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Can the combination of bladder ultrasonography and urinary cytodiagnosis replace cystoscopy in the diagnosis and follow-up of tumors of the bladder?].
    Cariou G; Maaraoui N; Cortesse A
    Prog Urol; 1997 Feb; 7(1):51-5. PubMed ID: 9116739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Cancer-Specific Methylation of Gene Combination for the Diagnosis of Bladder Cancer.
    Zhang N; Chen S; Wu L; Wu Y; Jiang G; Shao J; Chen L; Sun J; Na R; Wang X; Xu J
    J Cancer; 2019; 10(26):6761-6766. PubMed ID: 31777606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical usefulness of nuclear matrix protein-22 in patients with end-stage renal disease and microscopic hematuria.
    Trojan B; Tang A; Chandrapal J; Filleur S; Nelius T
    Ren Fail; 2013; 35(1):72-6. PubMed ID: 23151051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of urine cytology in the workup of asymptomatic microscopic hematuria in low-risk patients.
    Feifer AH; Steinberg J; Tanguay S; Aprikian AG; Brimo F; Kassouf W
    Urology; 2010 Jun; 75(6):1278-82. PubMed ID: 20138655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multidetector computed tomography virtual cystoscopy: an effective diagnostic tool in patients with hematuria.
    Kuehhas FE; Weibl P; Tosev G; Schatzl G; Heinz-Peer G
    Urology; 2012 Feb; 79(2):270-6. PubMed ID: 22310741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.
    Kim WT; Jeong P; Yan C; Kim YH; Lee IS; Kang HW; Kim YJ; Lee SC; Kim SJ; Kim YT; Moon SK; Choi YH; Kim IY; Yun SJ; Kim WJ
    Oncotarget; 2016 Sep; 7(36):58193-58202. PubMed ID: 27528424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunocytology in the assessment of patients with asymptomatic hematuria.
    Schmitz-Dräger BJ; Tirsar LA; Schmitz-Dräger C; Dörsam J; Mellan Z; Bismarck E; Ebert T
    World J Urol; 2008 Feb; 26(1):31-7. PubMed ID: 18075743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer.
    Fantony JJ; Abern MR; Gopalakrishna A; Owusu R; Jack Tay K; Lance RS; Inman BA
    Urol Oncol; 2015 Sep; 33(9):387.e1-6. PubMed ID: 26027762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
    Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
    Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin.
    Kenney DM; Geschwindt RD; Kary MR; Linic JM; Sardesai NY; Li ZQ
    Tumour Biol; 2007; 28(2):57-62. PubMed ID: 17259754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.
    Fantony JJ; Longo TA; Gopalakrishna A; Owusu R; Lance RS; Foo WC; Inman BA; Abern MR
    Cancer Biomark; 2017; 18(4):381-387. PubMed ID: 28106542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer.
    Eissa S; Labib RA; Mourad MS; Kamel K; El-Ahmady O
    Eur Urol; 2003 Dec; 44(6):687-94. PubMed ID: 14644121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
    Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers.
    Bangma CH; Loeb S; Busstra M; Zhu X; El Bouazzaoui S; Refos J; Van Der Keur KA; Tjin S; Franken CG; van Leenders GJ; Zwarthoff EC; Roobol MJ
    Eur Urol; 2013 Jul; 64(1):41-7. PubMed ID: 23478169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.